J&J seeks FDA green light for new use of Nucynta XR tablets; Depomed reports $8.6M loss in 3Q;

> West ($WST), a maker of products for injected drugs, has teamed up drug-delivery specialist Vetter to make filled Daikyo Crystal Zenith syringes. Release

> Johnson & Johnson ($JNJ) has asked the FDA to approved its extended-release Nucynta (tapentadol) tablets for pain from diabetic peripheral neuropathy. Release

> Depomed ($DEPO), a developer and provider of extended-release drugs, reported a net loss of $8.6 million in the third quarter, compared with net income of $1.9 million for the same period last year. Release

> Oxford Pharmascience, a developer of new formulations of generic drugs, has raised more than £1.1 million to fund its programs and its business in Brazil. Article

> Halozyme ($HALO) provided upbeat data from an early trial of its fast-acting drug tech used with insulin in patients with type 1 diabetes. Release